Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Mitchell

Critical Care Medicine Charleston, SC Medical Doctor

NPI 1205886124 CMS profile 54853

125 Doughty St Ste 200, Charleston, SC 29403

Open in the dashboard

General payments

$9,568

482 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$116,925 paid to institutions, not to them · program years 2019–2024

Through program year 2025, John Mitchell of Charleston, SC is reported in the CMS Open Payments database as having received $9,568 across 482 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $116,925 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,109 99
2024 General $2,041 97
2023 General $2,073 100
2022 General $1,615 85
2021 General $1,128 69
2020 General $239 15
2019 General $364 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Mitchell
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to John Mitchell were reported at $2,109. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year John Mitchell Critical Care Medicine median Middle half National median
2019 $364 $149 $51–$535 $163
2020 $239 $110 $30–$325 $114
2021 $1,128 $125 $34–$403 $132
2022 $1,615 $157 $49–$582 $149
2023 $2,073 $162 $56–$621 $160
2024 $2,041 $168 $53–$634 $164
2025 $2,109 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,540 84 payments
  2. Jazz Pharmaceuticals Inc. $1,074 54 payments
  3. GlaxoSmithKline, LLC. $992 57 payments
  4. Insmed, Inc. $723 32 payments
  5. Axsome Therapeutics, Inc. $527 23 payments
  6. Genzyme Corporation $443 19 payments
  7. Regeneron Healthcare Solutions, Inc. $403 16 payments
  8. Actelion Pharmaceuticals US, Inc. $396 26 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $391 21 payments
  10. Harmony Biosciences LLC $343 19 payments
  11. Other $2,736 131 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,336 478 payments
  2. Education $233 4 payments
Products named General payments · program years 2019–2025
  1. XYWAV $1,033 51 payments
  2. Arikayce $690 30 payments
  3. TRELEGY ELLIPTA $670 38 payments
  4. TEZSPIRE $551 27 payments
  5. Sunosi $527 23 payments
  6. DUPIXENT $443 19 payments
  7. FASENRA $426 21 payments
  8. BREZTRI $410 22 payments
  9. OPSUMIT $364 25 payments
  10. UPTRAVI $360 25 payments
  11. Other $5,058 248 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

1,969

Median for Critical Care (Intensivists): 406

Drug cost

$933,906

Median for Critical Care (Intensivists): $197,260

Branded share of claims

53.5%

Median for Critical Care (Intensivists): 69%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xywav Sodium,calcium,mag,pot Oxybate Brand 26 $423,240
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 150 $138,058
Fasenra Pen Benralizumab Brand 13 $72,494
Xolair Omalizumab Brand 15 $46,906
Breo Ellipta Fluticasone/Vilanterol Brand 75 $37,380
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 48 $28,751
Eliquis Apixaban Brand 26 $22,487
Xarelto Rivaroxaban Brand 15 $21,376
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 24 $19,698
Sunosi Solriamfetol Hcl Brand 17 $18,892

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,531 Part D prescribers listed as Critical Care (Intensivists); they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$236,389

Of which drugs: $32,581

Medicare patients

1,323

Average age 75

Services billed

4,359

634 women, 689 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 38%
Ischemic heart disease 36%
Atrial fibrillation 32%
COPD 31%
Heart failure 30%
Chronic kidney disease 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from recombinant dna 90673 Office 29 29 $2,373

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XYWAV
$385 26 —
Sunosi
$180 17 —
TEZSPIRE
$168 — —
DUPIXENT
$117 — —
TRELEGY ELLIPTA
$117 150 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

482 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record